1 Ocak 2019 Dergi makalesi Açık Erişim

Unal, Gokhan; Dokumaci, Alim Huseyin; Ozkartal, Ceren Sahin; Yerer, Mukerrem Betul; Aricioglu, Feyza

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <controlfield tag="001">75969</controlfield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="v">314</subfield>
    <subfield code="p">CHEMICO-BIOLOGICAL INTERACTIONS</subfield>
  </datafield>
  <controlfield tag="005">20210316043228.0</controlfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Schizophrenia cannot be treated sufficiently with existing antipsychotic drugs. Taken into account that increased Glycogen Synthase Kinase 3 Beta (GSK-3 beta) activity is associated with schizophrenia pathophysiology and certain antipsychotics can be able to decrease GSK3 beta activity, inhibition of GSK-3 beta activity could be a novel approach for the treatment of schizophrenia. In the present study MK-801, a widely used chemical for the in vivo/in vitro modeling of schizophrenia was selected to evoke a detrimental effect on cellular survival via GSK3 beta and related proteins. A limited number of studies have reported the curative effects of famotidine, an antiulcer drug, in schizophrenic patients. To the best of our knowledge, no study investigated the molecular mechanism of the beneficial effect of famotidine in the patients. A recent study based on computerized drug modeling software (docking) indicated that famotidine might inhibit the GSK3 beta activity due to its chemical structure independent from histaminergic receptors. In this study, we aimed to investigate the effects of famotidine on the Akt/GSK-3 beta/beta-catenin signaling pathway on SH-SY5Y neuroblastoma cells in the presence of MK-801. We investigated the effects of famotidine, olanzapine (an antipsychotic drug), and SB 415286 (specific GSK-3 beta inhibitor), on the basal cellular survival and MK-801 induced neuronal death beside of Akt/GSK-3 beta/beta-catenin protein and gene expressions in SH-SY5Y cells. Cell viability, protein and gene expressions were determined by the real-time cell analysis (xCELLigence) system, western blotting and real-time polymerase chain reactions (Rt-PCR), respectively. Our findings suggested that MK-801 administration decreased cell survival probably via the increasing GSK-3 beta gene expression and activity in the SH-SY5Y cells. Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3 beta activity. Overall, the present results suggest that famotidine has a neuroprotective effect against MK-801 via modulation of the Akt/GSK-3 beta/beta-catenin signaling pathway, an important mechanism in schizophrenia neurobiology.</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3 beta/beta-catenin signaling pathway in the SH-SY5Y cell line</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
    <subfield code="o">oai:zenodo.org:75969</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Erciyes Univ, Fac Pharm, Dept Pharmacol, Kayseri, Turkey</subfield>
    <subfield code="a">Unal, Gokhan</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:2a85c8836455214665dd605b3b16ee66</subfield>
    <subfield code="s">262</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/75969/files/bib-b9082369-4de3-41bc-b8b1-423ee21152c9.txt</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="2">doi</subfield>
    <subfield code="a">10.1016/j.cbi.2019.108823</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Erciyes Univ, Fac Pharm, Dept Pharmacol, Kayseri, Turkey</subfield>
    <subfield code="a">Dokumaci, Alim Huseyin</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ozkartal, Ceren Sahin</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Erciyes Univ, Fac Pharm, Dept Pharmacol, Kayseri, Turkey</subfield>
    <subfield code="a">Yerer, Mukerrem Betul</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Erciyes Univ, Fac Pharm, Dept Pharmacol, Kayseri, Turkey</subfield>
    <subfield code="a">Aricioglu, Feyza</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2019-01-01</subfield>
  </datafield>
</record>